Illumina Rejects Roche’s Offer | Chemical & Engineering News
Volume 90 Issue 7 | p. 20 | Concentrates
Issue Date: February 13, 2012

Illumina Rejects Roche’s Offer

Department: Business
Keywords: diagnostics, genetic analysis, gene sequencing, acquisition

Illumina’s board has rejected Roche’s $5.7 billion takeover bid. Claiming that the offer undervalues the company’s gene-sequencing business and growth prospects, the board recommends that shareholders not offer their shares to Roche. As the growth of the genetic analysis industry accelerates, “Illumina is singularly positioned to expand its market leadership and to deliver value to our stockholders that is far superior to Roche’s offer,” Illumina CEO Jay T. Flatley says. Roche says it is disappointed in the recommendation and Illumina’s refusal to negotiate a merger. Roche is advancing plans to name its own candidates for election to Illumina’s board.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment